First Command Bank reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,037 shares of the company’s stock after selling 445 shares during the quarter. Johnson & Johnson makes up about 1.0% of First Command Bank’s holdings, making the stock its 18th largest position. First Command Bank’s holdings in Johnson & Johnson were worth $2,075,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of the stock. Virtus ETF Advisers LLC purchased a new stake in Johnson & Johnson in the second quarter worth $25,000. Krane Funds Advisors LLC purchased a new stake in Johnson & Johnson in the second quarter worth $26,000. Crewe Advisors LLC increased its position in Johnson & Johnson by 725.9% in the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after buying an additional 196 shares during the last quarter. Permanens Capital L.P. increased its position in Johnson & Johnson by 50.0% in the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after buying an additional 100 shares during the last quarter. Finally, Personal Wealth Partners purchased a new stake in Johnson & Johnson in the second quarter worth $73,000. Institutional investors and hedge funds own 72.05% of the company’s stock.
Shares of NYSE JNJ opened at $135.17 on Thursday. The stock has a market cap of $344.99 billion, a PE ratio of 16.52, a price-to-earnings-growth ratio of 2.21 and a beta of 0.69. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The stock has a fifty day moving average of $130.30 and a 200-day moving average of $134.83.
JNJ has been the subject of a number of recent research reports. Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Barclays initiated coverage on Johnson & Johnson in a research report on Friday, June 21st. They issued a “hold” rating and a $140.00 target price for the company. Morgan Stanley reissued an “equal weight” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Wells Fargo & Co decreased their target price on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday. Finally, Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Friday, October 11th. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $150.91.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: What is the Book Value of a Share?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.